BioCryst
Pharmaceuticals, Inc., BCRX today announced that results from its
successful OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical
trial of orally-administered BCX4161 in patients with hereditary angioedema
(HAE) will be presented as a late-breaker oral presentation at the 23^rd EADV
Congress taking place in Amsterdam October 8-12, 2014.
The presentation titled "BCX4161, an Oral Kallikrein Inhibitor, is effective
and safe in the Prophylaxis of Acute Attacks in Patients with Hereditary
Angioedema: Results of the Phase 2 Trial OPuS-1," will be presented by Marcus
Maurer MD, Professor of Dermatology and Allergy, Charité-Universitäsmedizin,
Berlin and the principal investigator for OPuS-1. The presentation will take
place during the "Late Breaking News in Dermatology" session on Saturday,
October 11 at 1:00 PM Central European Time.
OPuS-1 evaluated 400 mg of BCX4161 administered three times a day for 28 days
in HAE patients with a high attack frequency (≥ 1 per week), in a randomized,
double-blind, placebo-controlled, two-period cross-over design. The primary
goals for the trial were to estimate the degree of efficacy of BCX4161 in
reducing the frequency of angioedema attacks, and to evaluate the safety and
tolerability of 28 days of BCX4161 treatment. The trial met the primary
efficacy endpoint and all other objectives established for the trial.
BioCryst expects to initiate its OPuS-2 trial to evaluate the efficacy and
safety of BCX4161 treatment for 12 weeks in patients with HAE before the end
of 2014.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in